Thind M, et al. - Researchers used Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, a nationwide US registry of atrial fibrillation (AF) patients, to determine the incidence of major adverse outcomes in patients with asymptomatic vs symptomatic AF. Comparisons were made for stroke/non-CNS embolism, major adverse cardiovascular and neurologic events (MACNE), bleeding, and death in 9,319 asymptomatic (defined by European Heart Rhythm Association (EHRA) score =1 or “no symptoms”) vs symptomatic patients. They observed a higher likelihood of having permanent/persistent AF in physician defined asymptomatic patients vs those with symptoms. According to symptom status, no variance was seen in CHA₂DS₂-VASc scores. Patients with asymptomatic (EHRA=1) and symptomatic AF were found to be similar in terms of risk of first stroke/non-CNS embolism, MACNE, bleeding, and death, after adjustment.